 SEATTLE--BUSINESS WIRE--Alpine Immune Sciences, Inc. NASDAQ:ALPN, a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmuneinflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common stock and prefunded warrants, as described below, in a private placement with certain institutional and other accredited investors for gross proceeds to Alpine of approximately 91 millio 